Clozapine use in a forensic population in a New South Wales prison hospital

Australian and New Zealand Journal of Psychiatry

Volumn 42, Issue 2, 2008, Pages 141-146

  Martin, Adam ^a   O'Driscoll, Coón ^a   Samuels, Anthony ^a  

^a JUSTICE HEALTH AND FORENSIC MENTAL HEALTH NETWORK   (Australia)

Author keywords

Adverse effects; Clozapine; Forensic psychiatry; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CLOZAPINE; METHADONE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AUSTRALIA; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; DRUG WITHDRAWAL; FORENSIC PSYCHIATRY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; INTRAVENOUS DRUG ABUSE; LIVER DYSFUNCTION; NEUTROPENIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; PERSONALITY DISORDER; PRESCRIPTION; PRISON; PSYCHOSIS; PULSE RATE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CRIME; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG MONITORING; DRUG RESISTANCE; FORENSIC PSYCHIATRY; HEALTH STATUS; HOSPITALS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; NEW SOUTH WALES; PATIENT DROPOUTS; PRISONERS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEIZURES; SUBSTANCE-RELATED DISORDERS;

EID: 38349182413     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670701787529     Document Type: Review

References (27)

1. Kane, J., Honifeld, G. and Singer, J. (1988) Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry, 45, pp. 789-796.
2. Hagger, C., Buckley, P. and Kenny, JT (1993) Improvement in cognitive functions in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry, 34, pp. 702-712.
3. Glazer, WM and Dickson, RA. (1998) Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry, 59, pp. 8-14.
4. Chengappa, KN, Vasile, J. and Levine, J. (2002) Clozapine: Its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res, 53, pp. 1-6.
5. Volavka, J., Zito, JM and Vitrai, J. (1993) Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol, 13, pp. 287-289.
6. Meltzer, HY. (1998) Suicide in schizophrenia: Risk factors and clozapine treatment. J Clin Psychiatry, 59, pp. 15-20.
7. Buscema, CA and Abbasi, QA. (2000) An algorithm for the treatment of schizophrenia in the correctional setting: The Forensic Algorithm Project. J Clin Psychiatry, 61, pp. 767-783.
8. Swinton, M. and Haddock, A. (2000) Clozapine in special hospital: A retrospective case-control study. J Forensic Psychiatry, 11, pp. 587-596.
9. Miller, DD. (2000) Review and management of clozapine side effects. J Clin Psychiatry, 61, pp. 14-17.
10. Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL and Schaaf, JA. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med, 329, pp. 162-167.
11. Killian, JG, Kerr, K. and Lawrence, C. (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet, 354, pp. 1841-1845.
12. Reinders, J., Parsonage, W., Lange, D., Potter, M. and Plever, S. (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry, 38, pp. 915-922.
13. Merrill, DB, Dec, GW and Goff, DC. (2005) Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol, 25, pp. 32-41.
14. Henderson, DC. (2001) Clozapine: Diabetes mellitus, weight gain and lipid abnormalities. J Clin Psychiatry, 62, pp. 39-44.
15. Umbricht, DS, Pollack, S. and Kane, JM. (1994) Clozapine and weight gain. J Clin Psychiatry, 55, pp. 157-160.
16. Pacia, SV and Devinsky, O. (1994) Clozapine-related seizures: Experience with 5,629 patients. Neurology, 44, pp. 2247-2249.
17. Toth, P. and Frankenburg, FR. (1994) Clozapine and seizures: A review. Can J Psychiatry, 39, pp. 236-238.
18. Hummer, M., Kurz, M., Kurzthaler, I., Oberbauer, H., Miller, C. and Fleischhacker, WW. (1997) Hepatotoxicity of clozapine. J Clin Psychopharmacol, 17, pp. 314-317.
19. Thatcher, GW, Cates, M. and Blair, B. (1995) Clozapine induced toxic hepatitis. Am J Psychiatry, 152, pp. 296-297.
20. Rogers, DP and Shramko, JK. (2000) Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy, 20, pp. 1092-1095.
21. Davydov, L. and Botts, SR. (2001) Clozapine-induced hypersalivation. Ann Pharmacother, 34, pp. 662-665.
22. MacGillivray, S., Cooper, SJ, English, B., Willimas, B. and Millar, H. (2003) Predictors of discontinuation on clozapine: A population study. Ir J Psychol Med, 20, pp. 115-118.
23. Guy, W. (1976) ECDEU assessment manual for psychopharmacology, US Dept of Health and Human Services, Rockville, MD
24. Breier, A., Schreiber, JL, Dyer, J. and Pickar, D. (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry, 48, pp. 239-246.
25. McGorry, P., Killackey, E., Elkins, K., Lambert, M. and Lambert, T. (2003) Summary Australian and New Zealand clinical practice guidelines for the treatment of schizophrenia. Australas Psychiatry, 11, pp. 136-147.
26. National Institute for Clinical Excellence (2002) Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care, Abba Litho Sales, London
27. Edwards, J., Maude, D. and Herman-Doig, T. (2002) A service response to prolonged recovery in early psychosis. Psychiatr Serv, 53, pp. 1067-1069.